Because changing the way medicines are delivered can improve patient’s life drastically. With Lauriad^® we are committed to optimizing the existing therapeutic offer, bringing out new « best-in-disease » drugs.

Vectans Pharma is glad to inform you that BfArM granted a 3-year exemption of the sunset clause for LORAMYC^® 50 mg, a muco‐adhesive buccal tablets issued from the Lauriad Technology, an innovative and patented drug delivery system ensuring targeted diffusion of Miconazole. In addition to Germany, LORAMYC^® is also registered in other European countries such as the United Kingdom, France and Italy. LORAMYC^® also benefits from an international presence through international licensing agreements in the United States and Asian countries.